Effects of short-term glucocorticoids on cardiovascular biomarkers

Daniel J. Brotman, John P. Girod, Mario J. Garcia, Jeetesh V. Patel, Manjula Gupta, Amy Posch, Sue Saunders, Gregory Y H Lip, Sarah Worley, Sethu Reddy

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Context: Glucocorticoids are known to acutely increase blood pressure, suppress inflammation, and precipitate insulin resistance. However, the short-term effects of glucocorticoids on other cardiovascular risk factors remain incompletely characterized. Objective: Our objective was to determine the effects of a short course of dexamethasone on multiple cardiovascular biomarkers and to determine whether suppression of morning cortisol in response to low-dose dexamethasone is correlated with cardiovascular risk markers in healthy volunteers. Design: We conducted a randomized, double-blind, placebo-controlled study. Setting: The study took place in a tertiary care hospital. Study subjects: Twenty-five healthy male volunteers, ages 19-39 yr, participated in the study. Intervention: Subjects received either 3 mg dexamethasone twice daily or placebo for 5 d. Subjects also underwent a low-dose (0.5 mg) overnight dexamethasone suppression test. Measures: Parameters examined before and after the 5-d intervention included heart rate, blood pressure, weight, fasting lipid variables, homocysteine, renin, aldosterone, insulin resistance (homeostasis model assessment), high-sensitivity C-reactive protein, B-type natriuretic peptide, flow-mediated and nitroglycerin-mediated brachial artery dilatation, and heart rate recovery after exercise. All measurements were done in the morning hours in the fasting state. Results: Dexamethasone increased systolic blood pressure, weight, B-type natriuretic peptide, and high-density-lipoprotein-cholesterol. Dexamethasone decreased resting heart rate, high-sensitivity Creactive protein, and aldosterone and tended to attenuate nitroglycerin-mediated vasodilatation. There was no effect on flow-mediated vasodilatation, diastolic blood pressure, triglycerides, low-densitylipoprotein-cholesterol, nonesterified fatty acids, homocysteine, or heart rate recovery. The response of circulating cortisol to low-dose dexamethasone had no significant correlation with any of the cardiovascular risk markers. Conclusions: Short-term glucocorticoids elicits both favorable and unfavorable effects on different cardiovascular risk factors. Manipulation of specific glucocorticoid-responsive physiological pathways deserves further study.

Original languageEnglish (US)
Pages (from-to)3202-3208
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume90
Issue number6
DOIs
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

Biomarkers
Dexamethasone
Glucocorticoids
Blood pressure
Blood Pressure
Heart Rate
Brain Natriuretic Peptide
Nitroglycerin
Homocysteine
Aldosterone
Vasodilation
Insulin Resistance
Hydrocortisone
Fasting
Healthy Volunteers
Placebos
Insulin
Weights and Measures
Recovery
Brachial Artery

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Brotman, D. J., Girod, J. P., Garcia, M. J., Patel, J. V., Gupta, M., Posch, A., ... Reddy, S. (2005). Effects of short-term glucocorticoids on cardiovascular biomarkers. Journal of Clinical Endocrinology and Metabolism, 90(6), 3202-3208. https://doi.org/10.1210/jc.2004-2379

Effects of short-term glucocorticoids on cardiovascular biomarkers. / Brotman, Daniel J.; Girod, John P.; Garcia, Mario J.; Patel, Jeetesh V.; Gupta, Manjula; Posch, Amy; Saunders, Sue; Lip, Gregory Y H; Worley, Sarah; Reddy, Sethu.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 90, No. 6, 06.2005, p. 3202-3208.

Research output: Contribution to journalArticle

Brotman, DJ, Girod, JP, Garcia, MJ, Patel, JV, Gupta, M, Posch, A, Saunders, S, Lip, GYH, Worley, S & Reddy, S 2005, 'Effects of short-term glucocorticoids on cardiovascular biomarkers', Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 6, pp. 3202-3208. https://doi.org/10.1210/jc.2004-2379
Brotman, Daniel J. ; Girod, John P. ; Garcia, Mario J. ; Patel, Jeetesh V. ; Gupta, Manjula ; Posch, Amy ; Saunders, Sue ; Lip, Gregory Y H ; Worley, Sarah ; Reddy, Sethu. / Effects of short-term glucocorticoids on cardiovascular biomarkers. In: Journal of Clinical Endocrinology and Metabolism. 2005 ; Vol. 90, No. 6. pp. 3202-3208.
@article{2299a91db11e413f8869c09d8d95fa1c,
title = "Effects of short-term glucocorticoids on cardiovascular biomarkers",
abstract = "Context: Glucocorticoids are known to acutely increase blood pressure, suppress inflammation, and precipitate insulin resistance. However, the short-term effects of glucocorticoids on other cardiovascular risk factors remain incompletely characterized. Objective: Our objective was to determine the effects of a short course of dexamethasone on multiple cardiovascular biomarkers and to determine whether suppression of morning cortisol in response to low-dose dexamethasone is correlated with cardiovascular risk markers in healthy volunteers. Design: We conducted a randomized, double-blind, placebo-controlled study. Setting: The study took place in a tertiary care hospital. Study subjects: Twenty-five healthy male volunteers, ages 19-39 yr, participated in the study. Intervention: Subjects received either 3 mg dexamethasone twice daily or placebo for 5 d. Subjects also underwent a low-dose (0.5 mg) overnight dexamethasone suppression test. Measures: Parameters examined before and after the 5-d intervention included heart rate, blood pressure, weight, fasting lipid variables, homocysteine, renin, aldosterone, insulin resistance (homeostasis model assessment), high-sensitivity C-reactive protein, B-type natriuretic peptide, flow-mediated and nitroglycerin-mediated brachial artery dilatation, and heart rate recovery after exercise. All measurements were done in the morning hours in the fasting state. Results: Dexamethasone increased systolic blood pressure, weight, B-type natriuretic peptide, and high-density-lipoprotein-cholesterol. Dexamethasone decreased resting heart rate, high-sensitivity Creactive protein, and aldosterone and tended to attenuate nitroglycerin-mediated vasodilatation. There was no effect on flow-mediated vasodilatation, diastolic blood pressure, triglycerides, low-densitylipoprotein-cholesterol, nonesterified fatty acids, homocysteine, or heart rate recovery. The response of circulating cortisol to low-dose dexamethasone had no significant correlation with any of the cardiovascular risk markers. Conclusions: Short-term glucocorticoids elicits both favorable and unfavorable effects on different cardiovascular risk factors. Manipulation of specific glucocorticoid-responsive physiological pathways deserves further study.",
author = "Brotman, {Daniel J.} and Girod, {John P.} and Garcia, {Mario J.} and Patel, {Jeetesh V.} and Manjula Gupta and Amy Posch and Sue Saunders and Lip, {Gregory Y H} and Sarah Worley and Sethu Reddy",
year = "2005",
month = "6",
doi = "10.1210/jc.2004-2379",
language = "English (US)",
volume = "90",
pages = "3202--3208",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Effects of short-term glucocorticoids on cardiovascular biomarkers

AU - Brotman, Daniel J.

AU - Girod, John P.

AU - Garcia, Mario J.

AU - Patel, Jeetesh V.

AU - Gupta, Manjula

AU - Posch, Amy

AU - Saunders, Sue

AU - Lip, Gregory Y H

AU - Worley, Sarah

AU - Reddy, Sethu

PY - 2005/6

Y1 - 2005/6

N2 - Context: Glucocorticoids are known to acutely increase blood pressure, suppress inflammation, and precipitate insulin resistance. However, the short-term effects of glucocorticoids on other cardiovascular risk factors remain incompletely characterized. Objective: Our objective was to determine the effects of a short course of dexamethasone on multiple cardiovascular biomarkers and to determine whether suppression of morning cortisol in response to low-dose dexamethasone is correlated with cardiovascular risk markers in healthy volunteers. Design: We conducted a randomized, double-blind, placebo-controlled study. Setting: The study took place in a tertiary care hospital. Study subjects: Twenty-five healthy male volunteers, ages 19-39 yr, participated in the study. Intervention: Subjects received either 3 mg dexamethasone twice daily or placebo for 5 d. Subjects also underwent a low-dose (0.5 mg) overnight dexamethasone suppression test. Measures: Parameters examined before and after the 5-d intervention included heart rate, blood pressure, weight, fasting lipid variables, homocysteine, renin, aldosterone, insulin resistance (homeostasis model assessment), high-sensitivity C-reactive protein, B-type natriuretic peptide, flow-mediated and nitroglycerin-mediated brachial artery dilatation, and heart rate recovery after exercise. All measurements were done in the morning hours in the fasting state. Results: Dexamethasone increased systolic blood pressure, weight, B-type natriuretic peptide, and high-density-lipoprotein-cholesterol. Dexamethasone decreased resting heart rate, high-sensitivity Creactive protein, and aldosterone and tended to attenuate nitroglycerin-mediated vasodilatation. There was no effect on flow-mediated vasodilatation, diastolic blood pressure, triglycerides, low-densitylipoprotein-cholesterol, nonesterified fatty acids, homocysteine, or heart rate recovery. The response of circulating cortisol to low-dose dexamethasone had no significant correlation with any of the cardiovascular risk markers. Conclusions: Short-term glucocorticoids elicits both favorable and unfavorable effects on different cardiovascular risk factors. Manipulation of specific glucocorticoid-responsive physiological pathways deserves further study.

AB - Context: Glucocorticoids are known to acutely increase blood pressure, suppress inflammation, and precipitate insulin resistance. However, the short-term effects of glucocorticoids on other cardiovascular risk factors remain incompletely characterized. Objective: Our objective was to determine the effects of a short course of dexamethasone on multiple cardiovascular biomarkers and to determine whether suppression of morning cortisol in response to low-dose dexamethasone is correlated with cardiovascular risk markers in healthy volunteers. Design: We conducted a randomized, double-blind, placebo-controlled study. Setting: The study took place in a tertiary care hospital. Study subjects: Twenty-five healthy male volunteers, ages 19-39 yr, participated in the study. Intervention: Subjects received either 3 mg dexamethasone twice daily or placebo for 5 d. Subjects also underwent a low-dose (0.5 mg) overnight dexamethasone suppression test. Measures: Parameters examined before and after the 5-d intervention included heart rate, blood pressure, weight, fasting lipid variables, homocysteine, renin, aldosterone, insulin resistance (homeostasis model assessment), high-sensitivity C-reactive protein, B-type natriuretic peptide, flow-mediated and nitroglycerin-mediated brachial artery dilatation, and heart rate recovery after exercise. All measurements were done in the morning hours in the fasting state. Results: Dexamethasone increased systolic blood pressure, weight, B-type natriuretic peptide, and high-density-lipoprotein-cholesterol. Dexamethasone decreased resting heart rate, high-sensitivity Creactive protein, and aldosterone and tended to attenuate nitroglycerin-mediated vasodilatation. There was no effect on flow-mediated vasodilatation, diastolic blood pressure, triglycerides, low-densitylipoprotein-cholesterol, nonesterified fatty acids, homocysteine, or heart rate recovery. The response of circulating cortisol to low-dose dexamethasone had no significant correlation with any of the cardiovascular risk markers. Conclusions: Short-term glucocorticoids elicits both favorable and unfavorable effects on different cardiovascular risk factors. Manipulation of specific glucocorticoid-responsive physiological pathways deserves further study.

UR - http://www.scopus.com/inward/record.url?scp=21244458093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244458093&partnerID=8YFLogxK

U2 - 10.1210/jc.2004-2379

DO - 10.1210/jc.2004-2379

M3 - Article

C2 - 15769980

AN - SCOPUS:21244458093

VL - 90

SP - 3202

EP - 3208

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -